Table 1.
Specifications of contrast agents with hepatobiliary properties (gadobenate dimeglumine, gadoxetic acid) in comparison to a widely used extracellular agent (gadopentetate dimeglumine).
| Short chemical name | Gd-BOPTA | Gd-EOB-DTPA | Gd-DTPA |
|---|---|---|---|
| Generic/IUP name (111) | gadobenate dimeglumine |
gadoxetic acid |
gadopentetate dimeglumine |
| Vendor | Bracco Diagnostics | Bayer Healthcare Pharmaceuticals |
Bayer Healthcare Pharmaceuticals |
| Distribution name | MultiHance® | EU: Primovist® US: Eovist® |
Magnevist® |
| Osmolality [mosm/kg H2O] | 1970 | 884 | 1960 |
| Concentration [mol/l] | 0.5 | 0.25 | 0.5 |
| r1/r2 plasma relaxivity 1.5T * | 6.3 (6.0–6.6) 8.7 (7.8–9.6) |
6.9 (6.5–7.3) 8.7 (7.8–9.6) |
4.1 (3.9–4.3) 4.6 (3.8–5.4) |
| r1/r2 plasma relaxivity 3T * | 5.5 (5.2–5.8) 11.0 (10.0–12.0) |
6.2 (5.9–6.5) 11 (10–12) |
3.7 (3.5–3.9) 5.2 (4.3–6.1) |
| Excretion | predominantly renal, 3-5% biliary |
~ 50% renal excretion, ~50% biliary |
renal |
| Typical Dosage | 0.05 - 0.1 mmol/kg 0.1 - 0.2 ml/kg |
0.025-0.05 mmol/kg 0.1 - 0.2 ml/kg |
0.1-0.2 mmol/kg 0.2-0.4 ml/kg |
*
data according to Rohrer et al. (112)